Dehydroemetine

Dehydroemetine is a synthetic derivative of emetine, classified as an antiprotozoal agent with antiamoebic, antimalarial, and antileishmanial properties. It is structurally similar to emetine but has fewer side effects. The drug acts primarily by inhibiting protein synthesis in susceptible protozoa through arresting intra-ribosomal translocation of the tRNA-amino acid complex, specifically binding to the ribosomal 40S subunit and blocking polypeptide chain elongation. Dehydroemetine is used mainly for the treatment of invasive amoebiasis (intestinal and hepatic), particularly when first-line agents like metronidazole are ineffective or contraindicated. It has also been investigated for malaria and leishmaniasis. Due to its potential for severe adverse effects—especially cardiotoxicity—it is now rarely used except in refractory cases. The drug is rapidly absorbed after intramuscular administration and slowly excreted renally[1][2][3][5][6][7][8].

Brand names

Dehydroemetine

Other names

Dehydroemetine